11 November 2011 – Parsortix update

The group has announced that its 90% owned subsidiary Parsortix has confirmed that recent tests have shown that its blood cell separation device can capture prostrate cancer cells.  The technology has already been shown to capture breast cancer cells and the latest breakthrough is clearly a strong vindication for the technology.  The potential for the device is clearly exceptional and the shares remain a BUY.